Literature DB >> 34760983

Multimodality standard of care treatment of resectable and borderline resectable pancreatic cancer.

John P Neoptolemos1, Paula Ghaneh2, Thilo Hackert1.   

Abstract

Entities:  

Year:  2021        PMID： 34760983      PMCID： PMC8527429          DOI： 10.21037/hbsn-21-131

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN： 2304-3881            Impact factor:   7.293


× No keyword cloud information.
  5 in total

1.  FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.

Authors:  Thierry Conroy; Pascal Hammel; Mohamed Hebbar; Meher Ben Abdelghani; Alice C Wei; Jean-Luc Raoul; Laurence Choné; Eric Francois; Pascal Artru; James J Biagi; Thierry Lecomte; Eric Assenat; Roger Faroux; Marc Ychou; Julien Volet; Alain Sauvanet; Gilles Breysacher; Frédéric Di Fiore; Christine Cripps; Petr Kavan; Patrick Texereau; Karine Bouhier-Leporrier; Faiza Khemissa-Akouz; Jean-Louis Legoux; Béata Juzyna; Sophie Gourgou; Christopher J O'Callaghan; Claire Jouffroy-Zeller; Patrick Rat; David Malka; Florence Castan; Jean-Baptiste Bachet
Journal:  N Engl J Med       Date:  2018-12-20       Impact factor: 91.245

2.  Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.

Authors:  John P Neoptolemos; Daniel H Palmer; Paula Ghaneh; Eftychia E Psarelli; Juan W Valle; Christopher M Halloran; Olusola Faluyi; Derek A O'Reilly; David Cunningham; Jonathan Wadsley; Suzanne Darby; Tim Meyer; Roopinder Gillmore; Alan Anthoney; Pehr Lind; Bengt Glimelius; Stephen Falk; Jakob R Izbicki; Gary William Middleton; Sebastian Cummins; Paul J Ross; Harpreet Wasan; Alec McDonald; Tom Crosby; Yuk Ting Ma; Kinnari Patel; David Sherriff; Rubin Soomal; David Borg; Sharmila Sothi; Pascal Hammel; Thilo Hackert; Richard Jackson; Markus W Büchler
Journal:  Lancet       Date:  2017-01-25       Impact factor: 79.321

3.  A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.

Authors:  John P Neoptolemos; Deborah D Stocken; Helmut Friess; Claudio Bassi; Janet A Dunn; Helen Hickey; Hans Beger; Laureano Fernandez-Cruz; Christos Dervenis; François Lacaine; Massimo Falconi; Paolo Pederzoli; Akos Pap; David Spooner; David J Kerr; Markus W Büchler
Journal:  N Engl J Med       Date:  2004-03-18       Impact factor: 91.245

4.  Systemic therapy without radiation may be appropriate as neoadjuvant therapy for localized pancreas cancer.

Authors:  Scott Kizy; Ariella M Altman; Keith M Wirth; Schelomo Marmor; Jane Y C Hui; Todd M Tuttle; Emil Lou; Khalid Amin; Jason W Denbo; Eric H Jensen
Journal:  Hepatobiliary Surg Nutr       Date:  2020-06       Impact factor: 7.293

5.  Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Phase 2 Randomized Clinical Trial.

Authors:  Davendra P S Sohal; Mai Duong; Syed A Ahmad; Namita S Gandhi; M Shaalan Beg; Andrea Wang-Gillam; James L Wade; E Gabriela Chiorean; Katherine A Guthrie; Andrew M Lowy; Philip A Philip; Howard S Hochster
Journal:  JAMA Oncol       Date:  2021-03-01       Impact factor: 31.777
  5 in total
  2 in total

1.  The management strategy of pancreatic cancer in the era of systemic therapy-"Surgery First" or "Surgery Last"?

Authors:  Yinmo Yang; Xiaodong Tian
Journal:  Hepatobiliary Surg Nutr       Date:  2022-08       Impact factor: 8.265

2.  Quantitative definitions of prognostic indicators of resectable pancreatic cancer.

Authors:  Hang Sun; Huayu Yang; Yilei Mao
Journal:  Gland Surg       Date:  2022-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.